Integration of Whole-Genome Sequencing PrOfiles and ImmuNe StATus in Cancer

Inclusion Criteria: 1. Diagnosis of locally advanced or metastatic cutaneous/mucosal melanoma or pancreatic cancer, meeting the following characteristics: a. Melanoma i. Patients with histologically proven locally advanced or metastatic melanoma (stage IV), with intrinsic or acquired resistance to treatment with immune checkpoint inhibition (anti-PD1 antibody +/- ipilimumab) ii. Patients with locoregional or distant recurrence either during, or within 3 months after completion or discontinuation of (neo)adjuvant anti-PD1-based immunotherapy for stage III melanoma. b. Pancreatic cancer i. Patients with histologically proven metastatic pancreatic cancer with progression under or after standard first-line chemotherapy with FOLFIRINOX. 2. Patients must be willing and able to provide written informed consent and be willing and able to comply with the study protocol. 3. Patients must be ≥18 years of age. 4. Metastatic or locoregional lesion of which a tumour needle biopsy can be safely obtained according to routine clinical practice. Exclusion Criteria: \- Patients with metastatic or locally advanced lesions which are not considered to be technically and/or safely biopsied.